CONTENTS:
- Are Americans sobering up? New trends in alcohol consumption in the United States [Editorial]. Keyes K.M., p. 726-728.
- Contingency management interventions for substance use and addictive behaviours: Review of the United Kingdom evidence base. Getty C.A., McQuarrie T., Brobbin E., p. 729-746.
- Commentary on Getty et al.: Complementarity of harm reduction and contingency management. Roll J.M., p. 747-748.
- Drug use among people in prison: A global review of epidemiology, harms and interventions. Favril L., Strang J., Fazel S., p. 749-764.
- Social cognition in Korsakoff's syndrome: A meta-analysis. Wijnen K., Eikelboom W.S., Rensen Y.C.M., Janssen G.T.L., Kessels R.P.C., p. 765-776.
- Preventing gambling-related harm in adolescents (PRoGRAM-A), a secondary school-based social network intervention: Results from a pilot cluster randomised controlled trial. Dobbie F., Miller M., Niven A., Wardle H., Weir C., Ensor H., et al., p. 777-787.
- Commentary on Dobbie et al.: Preventing adolescent gambling-related harm - Is a universal approach sufficient? Richard J., p. 788-789.
- Secondary analysis of a combined harm-reduction treatment and extended-release naltrexone randomized clinical trial for alcohol use disorder: Differences across race, ethnicity and sex assigned at birth. Goldstein S.C., Weiss N.H., Yang M., Feldstein Ewing S.W., Collins S.E., p. 790-803.
- Alcohol approach-avoidance task behavior and brain potentials differentially predict ecologically assessed alcohol craving and consumption in early emerging adulthood. Cofresí R.U., Keerstock S., Kohen C.B., Piasecki T.M., Bartholow B.D., p. 804-824.
- Examining changes in the prevalence of cost-motivated alcohol reduction attempts in the context of a cost-of-living crisis and alcohol duty reforms: A population survey of risky drinkers in Great Britain, 2021-2024. Jackson S.E., Brown J., Angus C., Stevely A., Opazo Breton M., Brose L., et al., p. 825-838.
- Has alcohol consumption in England returned to pre-COVID-19 pandemic levels? A monthly population study, 2014 to 2024. Buss V.H., Oldham M., Jackson S.E., Shahab L., Angus C., Holmes J., et al., p. 839-850.
- Changes in wastewater measures of alcohol consumption in Alice Springs, Australia, 1 year after the introduction of restrictions on alcohol sales. Tscharke B., Livingston M., Clifford S., Zheng Q., Thai P.K., Verhagen R., et al., p. 851-860.
- Cannabis consumption in Australia 2018-2025: Socio-economic and regional trends from wastewater and survey data. Verhagen R., Gerber C., Thai P., Bade R., O'Brien J., Keller E.L., et al., p. 861-869.
- Development of a novel risk score reflecting the relative harm potential of synthetic cannabinoids based on prevalence estimates, well-documented intoxication cases and basic pharmacological data. Sommer M.J., Grafinger K.E., Hermanns-Clausen M., Auwärter V., p. 870-882.
- Telemedicine-assisted buprenorphine induction versus standard of care: A randomized controlled non-inferiority trial. Dhillon H.S., Ghosh A., Naik S., Nanjayya S., Verma A., Basu D., p. 883-893.
- Can a participant-referred 'study buddy' increase retention of rural people who use drugs in research? A multi-site, randomized trial. Young A.M., Lancaster K.E., Elman M.R., Bielavitz S., Cook R.R., Estadt A.T., et al., p. 894-907.
- Exploring the genetic overlap between substance use disorder and educational attainment. Cabana-Dominguez J., Vilar-Ribo L., Soler Artigas M., Alemany S., Llonga N., Carabi-Gassol P., et al., p. 908-921.
- Evaluating the optimal duration of medication treatment for opioid use disorder. Hayes C.J., Raciborski R.A., Acharya M., Noor N.B., Nunes E.V., Winhusen T.J., p. 922-933.
- Variations in US county-level trends in buprenorphine use, 2018-2022. Lefler T.W., Chai G., Goyal S., Song J., Xu J., Weissburg L.T., et al., p. 934-943.
- Estimating community-level prevalence of opioid use disorder: Extrapolating from Medicaid claims data and other publicly available data sources in Ohio, USA. Dowd W.N., Chen Q., Barbosa C., Sahinkoc H.M., Barocas J., Chhatwal J., et al., p. 944-954.
- Commentary on Dowd et al.: Beyond single data sources-Consistency checking and evidence synthesis for prevalence estimation. Jones H.E., Markoulidakis A., Hickman M., p. 955-956.
- Motivational smoking cessation counselling and community-based follow-up after hospitalisation for vascular disease: A randomised controlled trial. Pleym K., Sverre E., Weedon-Fekjær H., Kahlon M.S., Stugaard M., Husebye E., et al., p. 957-969.
- Heated tobacco product use and tobacco abstinence: A prospective cohort study. Ukai T., Shinozaki T., Tabuchi T., p. 970-981.
- Associations between county-level e-cigarette-inclusive Tobacco 21 law population coverage and e-cigarette use behaviors among United States adolescents in Monitoring the Future. Buszkiewicz J.H., Vander Woude C.A., Xie Y., Cook S., Peters B.U., Patrick M.E., et al., p. 982-993.
- Continuing use of e-cigarettes after stopping smoking and relapse: Secondary analysis of a large randomised controlled trial. Hajek P., Przulj D., Myers Smith K., Li J., Sasieni P., Ross L., et al., p. 994-997.
- Impact of study design decisions on identification of treatment initiators of medications for opioid use disorder. Roy P.J., Colvin R., Nickel K.B., Ross R.K., Durkin M.J., Suda K.J., et al., p. 998-1007.
- Correcting popular misconceptions about the origins of the Marihuana Tax Act of 1937. Hall W., Yeates S., p. 1008-1018.
- Addiction Lives: Isidore Obot. Berridge V., p. 1019-1020.
- Post-hoc subgroup analyses in clinical trials: Essential but methodologically constrained. Goldstein S.C., Weiss N.H., Collins S.E., p. 1021-1022.
- The need for a comprehensive opioid overdose prevention program in Iran. Malekifar P., Rahimi-Movaghar A., p. 1023-1024.